Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G.
Boehrer S, et al. Among authors: fabre c.
Blood. 2008 Feb 15;111(4):2170-80. doi: 10.1182/blood-2007-07-100362. Epub 2007 Oct 9.
Blood. 2008.
PMID: 17925489
Free article.